| 09th week of 2010 patent applcation highlights part 66 |
| Patent application number | Title | Published |
|---|
| 20100056291 | ADJUSTABLE LENGTH AND TORQUE RESISTANT GOLF SHAFT - An adjustable golf shaft having an upper shaft member, a lower shaft member and an inner rod. The upper shaft member includes an elongated bore therein with an upper bushing fixed within an upper end of the elongated bore therein. The lower shaft member has an elongated bore therein with a middle bushing fixed within an upper end of the elongated bore therein. The inner rod includes a lower end dimensioned to be fixed to a lower bushing, and an upper end dimensioned to be fixed to the upper bushing. The inner rod is adapted to slide within the middle bushing as the length of the shaft changes. The shaft also includes a fastener or locking mechanism, which secures the lower shaft member within the upper shaft member. | 2010-03-04 |
| 20100056295 | GOLF CLUB HEAD - A golf club head according to the present invention comprises a plurality of score lines on a face, and a stair-shaped portion comprising a plurality of steps formed on a side wall of the score line from a face side end of the side wall in a depth direction of the score line. | 2010-03-04 |
| 20100056296 | GOLF CLUB HEAD - A head of a first aspect is provided with a head body h | 2010-03-04 |
| 20100056297 | MULTI-PIECE GOLF CLUB HEAD WITH IMPROVED INERTIA - A multi-piece iron-type golf club head with a substantial weight member is disclosed and claimed. The golf club head includes a plurality of body members. A first body member includes a face, a rear surface, and a hosel. A viscoelastic material is attached to the rear surface, and a second body member is attached to the viscoelastic material. The second body member, which may be a weight member, has a substantially larger mass than in known golf clubs. The viscoelastic member may form a substantial part of the club head. The club head may also have a recess located in a top portion thereof between the heel and the toe and extending toward the sole. A low-density insert may be positioned within the recess. | 2010-03-04 |
| 20100056300 | MUTLI-LAYER GOLF BALL HAVING INNER COVERS WITH NON-PLANAR PARTING LINES - The invention comprises a golf ball. The golf ball is formed with a core, at least one intermediate layer, and a cover. The intermediate layer has a non-planar parting line. The molds used to form the intermediate layer have non-planar mating surfaces. The non-planar mating surfaces of the molds mesh, and when the intermediate layer is formed therein, the intermediate layer has a non-planar parting line thereon. If compression molding is used, hemispherical layer blanks may be pre-formed in the shape of the mold halves. To form the intermediate layer, the two blanks are compression molded together. If injection molding is used, a core is placed inside a mold chamber and layer material is injected into the mold chamber to form the intermediate layer about the core. If reaction injection molding is used, two or more reactive precursors are mixed and injected into the mold cavity, and they react to form the intermediate layer. Optional outer layers and a cover are molded on the intermediate layer to form a finished ball. | 2010-03-04 |
| 20100056301 | GOLF BALL - A golf ball | 2010-03-04 |
| 20100056303 | GOLF BALL MATERIAL, GOLF BALL AND METHOD FOR PREPARING GOLF BALL MATERIAL - The invention provides a golf ball material composed of an ionomeric resin composition obtained by melt-blending under applied heat one or more compounds selected from among UV/EB-curable materials with, in the presence of a peroxide, a non-ionomeric thermoplastic resin and an ionomeric resin; or of an ionomeric resin composition obtained by using, instead of the ionomeric resin, an acid-containing polymer base of the ionomeric resin and subjecting the acid-containing polymer composition similarly prepared by melt-blending under applied heat to an acid-neutralizing reaction with a metal ionic species. Methods for preparing such a material, and golf balls which include as a component therein a molding made of the golf ball material are also provided. The golf ball material has a good thermal stability, flow and processability, and can thus be used to obtain high-performance golf balls endowed with an excellent abrasion resistance, scuff resistance, durability and flexibility without a loss of rebound. | 2010-03-04 |
| 20100056305 | RECYCLABLE GOLF BALL AND METHOD THEREFOR - Distribution channels for returning used golf balls to the original manufacturers are disclosed. Incentives for golfers to return golf balls for recycling are also provided. | 2010-03-04 |
| 20100056306 | Retractable blowing exerciser - The present invention relates to a retractable blowing exerciser, wherein the round cup is designed into a taper shaped radial face for matching and positioning of the arc of the ball body, a neck pipe is positioned below the base of the round cup to connect the integrated retractable ring so that the flat round body of the ring folds into the integrated extension coefficient, people can adjust the distance depending on their height for playing in the ball blowing area and achieve the practical benefits of fitness and entertainment for users in all ages anytime and anywhere. | 2010-03-04 |
| 20100056310 | Apparatus With Mesh and Manducable Protrusion - An apparatus is provided, which includes a plurality of elongated strands having joinder regions uniting adjacent strands at a distance along a length of an outer perimeter of the elongated strands, the elongate strands being configured to couple together for a distance along their lengths. The elongated strands form a surface of a mesh when the joinder regions are coupled. The apparatus may further include a manducable protrusion coupled to the mesh and extending a distance away from an exterior surface of the mesh. | 2010-03-04 |
| 20100056313 | LIMITED SLIP DIFFERENTIAL - A limited slip differential includes a driving plate, backing plates, differential gear assemblies, and a transmission assembly engaged together inside a sealed casing where fluid is pumped. The driving plate has pairs of communicated openings for interlocking two gears of each gear assembly, which extend by opposite directions from the driving plate for separately engaging with the transmission assembly. While synchronously rotating the plates, the gear assemblies are alternatively soaked into the fluid and each permits the fluid passing among the gears for adjusting the rotational speed. In the event that the rotational speed difference of axle shafts of the vehicle exceeds a threshold value, the LSD applies at least one gear assembly to generate a back pressure and efficiently block the fluid passing through the gears for limiting mutual rotational speed difference, hence achieving a limited-slip effect. | 2010-03-04 |
| 20100056314 | Differential Device - A differential device differentially distributes a driving force to first and second axles. The differential device is comprised of a differential gear set configured to allow differential motion between the first and second axles, a casing rotatable about an axis, the casing housing and being drivingly coupled with the differential gear set and including a first end wall, a second end wall axially opposed to the first end wall, and a side wall disposed radially outward, which in combination with the first end wall and the second end wall defines a chamber configured to house the differential gear set, a clutch engageable with the differential gear set, a solenoid configured to drive the clutch, which is disposed adjacent to the first end wall, and a magnetic core fixed to the solenoid. The magnetic core is comprised of a sleeve portion snugly and slidably fitting around an outer periphery of the side wall to radially position the core and the solenoid in place. | 2010-03-04 |
| 20100056316 | GEAR TRANSMISSION - An external gear has a number of teeth differing from a number of teeth of an internal gear, and is maintaining in a meshing state with the internal gear. A center through hole and an offset through hole are formed in the external gear. The center through hole is formed at the center of the external gear, whereas the offset through hole is formed at a position offset from the center of the external gear. Column-shaped member of a carrier passes through the offset through hole. A pair of supporting members of the carrier respectively supports each end of the column-shaped member. A pair of grooves is formed on a surface of a shaft of a crank member at positions between which an eccentric rotation member of the crank member is interleaved. First rolling elements and first outer races are arranged between the supporting members and the grooves. The shaft of the crank member is supported so as to be capable of rotating with respect to the carrier and incapable of moving in its axial direction. | 2010-03-04 |
| 20100056317 | ADJUSTER - An adjustment fitting ( | 2010-03-04 |
| 20100056322 | CONTINUOUSLY VARIABLE TRANSMISSION - Inventive embodiments are directed to components, subassemblies, systems, and/or methods for continuously variable transmissions (CVT). In one embodiment, a control system is adapted to facilitate a change in the ratio of a CVT. In another embodiment, a control system includes a stator plate configured to have a plurality of radially offset slots. Various inventive traction planet assemblies and stator plates can be used to facilitate shifting the ratio of a CVT. In some embodiments, the traction planet assemblies include planet axles configured to cooperate with the stator plate. In one embodiment, the stator plate is configured to rotate and apply a skew condition to each of the planet axles. In some embodiments, a stator driver is operably coupled to the stator plate. Embodiments of a traction sun are adapted to cooperate with other components of the CVT to support operation and/or functionality of the CVT. Among other things, shift control interfaces for a CVT are disclosed. | 2010-03-04 |
| 20100056323 | TRANSMISSION - In a transmission having an input disk installed on an input shaft and an output disk installed on an output shaft, a pair of pressure rollers is provided to be movable along a two-axes connecting line of the axes of the input and output shafts, within a disk overlapping area that the input and output disks overlap with each other. The pressure roller pair is configured to sandwich the input and output disks while applying contact pressure from the outside disk faces at a position corresponding to a required transmission ratio, for creating a torque-transmission contacting portion by elastic deformation of the disks. A biasing device is provided for producing a biasing force from which the contact pressure arises. A biasing-force adjustment device is also provided for adjusting the biasing force to produce an appropriate magnitude of contact pressure suited to a shifting condition. | 2010-03-04 |
| 20100056324 | TRANSMISSION - In a transmission having an input disk, which is installed on an input shaft and whose outer peripheral edge is arranged in close proximity to an output shaft arranged parallel to the input shaft, and an output disk, which is installed on the output shaft and whose outer peripheral edge is arranged in close proximity to the input shaft, a pair of pressure rollers is provided to be movable along a two-axes connecting line of the axes of the input and output shafts, within a disk overlapping area that the input and output disks overlap with each other. The pressure roller pair is configured to sandwich the input and output disks while applying contact pressure from the outside disk faces at a position corresponding to a required transmission ratio, for creating a torque-transmission contacting portion by elastic deformation of the disks. | 2010-03-04 |
| 20100056326 | STEERING SYSTEMS AND METHODS FOR HYBRID VEHICLES - A steering system generally includes a steering gear for controlling a steer axle of the a hybrid vehicle in response to rotation of a steering wheel. The steering system also includes a power steering pump functionally connected to an internal combustion engine for supplying pressurized fluid to the steering gear. The steering system further includes an accumulator, a power steering controller, and a pressure sensor for monitoring the pressure of the accumulator. | 2010-03-04 |
| 20100056327 | Hybrid engine system - A hybrid engine and coupling system for use with a vehicle or other load which employs a motor/generator unit connected through controllable couplers to a kinetic energy storage device and to one or more internal combustion engine modules in a programmed manner. Several embodiments provide varying configurations to satisfy various power and packaging design requirements. | 2010-03-04 |
| 20100056331 | CONTROL DEVICE FOR OPERATING A GEAR BOX OF A VEHICLE, A SYSTEM FOR GEAR SHIFT AND PARKING BRAKE ACTUATION AND A VEHICLE COMPRISING A CONTROL DEVICE AND A SYSTEM - A control device for operating a gear box of a vehicle includes a selector for selection of two or more gear positions and for selection of a parking brake position. The parking brake position includes a first operating region which is adapted to gradually apply a parking brake and a second operating region which is adapted to fully apply a parking brake. | 2010-03-04 |
| 20100056332 | VEHICULAR CONTROL APPARATUS AND VEHICULAR CONTROL METHOD - When shifting an automatic transmission ( | 2010-03-04 |
| 20100056335 | Automatic transmission with part-throttle shifting - A power train for a machine is provided having a power source and a transmission, which includes a plurality of gears configured to produce multiple output ratios when selectively engaged. The power train also has a torque converter operatively coupling the power source and the transmission. A lockup clutch is associated with the torque converter, and the engagement of the lockup clutch is restricted so that the lockup clutch is engaged only when permissible gear ratios are actuated. The power train further has a controller in communication with the lockup clutch, the controller being configured to selectively engage the lockup clutch in either a first or a second shift mode with the number of permissible gear ratios being greater in the first shift mode than the second shift mode. | 2010-03-04 |
| 20100056336 | METHOD FOR ACTIVIATING A CLUTCH - A method for actuating a continuously variable clutch such that the torque to be transmitted by the clutch is continuously adjusted either electromechanically via an electromotive drive, hydraulically via a pressure actuator, or electromagnetically via an electromagnetic actuator. The torque transmitted by the clutch is adjusted by utilizing a position-dependent clutch torque specification. | 2010-03-04 |
| 20100056337 | Cruise Control System for Motor Vehicles - A cruise control system for motor vehicles controls the vehicle speed to a preset desired speed. The cruise control system includes an operating unit for switching the cruise control on and off, an accelerator pedal, normally present in the vehicle, for activating the cruise control and for presetting the desired speed, and a brake pedal, also normally present in the vehicle, for interrupting the active cruise control. The operating unit is configured as a single operating element, during whose actuation the cruise control is switched on or off as a function of the actual operating condition of the cruise control system. | 2010-03-04 |
| 20100056350 | PORTABLE EXERCISE DEVICE - A portable exerciser device for conducting two-person sit-ups is disclosed. The portable exerciser device has a hand-pulling assembly comprised of two hand holds joined by a connector. When combined into a kit, the additional elements may include a storage bag, shoe sole adhesive, shoe sole adhesive remover, one or more exerciser pads, and device information. | 2010-03-04 |
| 20100056353 | METHOD AND SYSTEM FOR PRODUCING FLUORIDE GAS AND FLUORINE-DOPED GLASS OR CERAMICS - The present invention relates generally to production of a fluoride gas and equivalents thereof, and fluorine-doped sodium silicate glass, glass ceramics, vitro ceramics and equivalents thereof. In one embodiment, the method includes providing a salt and an oxide in a reactor, heating the reactor to produce a vapor and the vitro ceramic and removing the vapor. | 2010-03-04 |
| 20100056354 | OPTICAL GLASS - Disclosed is an optical glass having a high refractive index and high moldability. | 2010-03-04 |
| 20100056355 | GAS PORE FORMER IN CELLULAR MONOLITHS - Porous ceramic articles may be produced by using a gas as a pore former, where the gas is injected into a ceramic precursor batch material and mixed. Pressure is then applied to mixture such that the gas liquefies. The pressure is maintained during formation of a green body, maintaining the gas in a liquefied state. After formation of the green body, the pressure is removed whereby the gas returns to a gaseous state, creating pores in the green body. The green body may then be fired to produce a porous ceramic article. | 2010-03-04 |
| 20100056398 | THICKENER COMPOSITION - Thickener systems which are suitable for preparing thickener compositions, and which systems consists of (A) at least one anionic surfactant A and (B) at least one polymer B comprising at least one hydrophobic group and preferably at least one hydrophilic group, wherein the concentration of the polymer B in a thickener composition is below the overlap concentration c* of the polymer, along with processes for preparing such compositions and uses thereof. | 2010-03-04 |
| 20100056399 | Polyelectrolyte Complexes For Oil And Gas Applications - A polyelectrolyte complex for the controlled release of an oil and gas field chemical selected from the group consisting of (a) a gel-forming or cross-linking agent, (b) a scale inhibitor, (c) a corrosion inhibitor, (d) an inhibitor of asphaltene or wax deposition, (e) a hydrogen sulfide scavenger, (f) a hydrate inhibitor, (g) a breaking agent, and a surfactant. | 2010-03-04 |
| 20100056401 | PARTIALLY NEUTRALIZED POLYHYDROXY ACIDS FOR WELL TREATMENTS - This relates to a method and composition for forming and utilizing a fluid in the oilfield services industry including exposing a polyacid and/or polyacid derivative to a preparation method, introducing the prepared polyacid and/or polyacid derivative to a fluid to form a treatment fluid, and treating a subterranean formation and/or a wellbore with the treatment fluid, wherein the viscosity of the treatment fluid is not observably reduced by introducing the prepared polyacid and/or polyacid derivative to a treatment fluid. This also relates to a method and composition for use in the oil field services industry including a prepared polyacid and/or polyacid derivative, a fluid, and a viscosity control agent, wherein the viscosity of the composition is not observably lower than if the prepared polyacid and/or polyacid derivative were not present. | 2010-03-04 |
| 20100056404 | METHOD FOR TREATING HYDROGEN SULFIDE-CONTAINING FLUIDS - The present invention relates generally to a method for treating hydrogen sulfide-containing fluids, more specifically to a method of treating hydrogen sulfide associated with petroleum and/or natural gas production. | 2010-03-04 |
| 20100056406 | Hydraulic Fluid and Method of Preventing Vapor Phase Corrosion - A metal glycol-based hydraulic fluid having vapor phase corrosion inhibition properties is disclosed. The hydraulic fluid can be used in food related applications. | 2010-03-04 |
| 20100056409 | COMPOSITIONS FOR PROCESSING OF SEMICONDUCTOR SUBSTRATES - Compositions useful in microelectronic device manufacturing for surface preparation and/or cleaning of wafer substrates such as microelectronic device precursor structures. The compositions can be employed for processing of wafers that have, or are intended to be further processed to include, copper metallization, e.g., in operations such as surface preparation, pre-plating cleaning, post-etching cleaning, and post-chemical mechanical polishing cleaning of microelectronic device wafers. The compositions contain (i) alkanolamine, (ii) quaternary ammonium hydroxide and (iii) a complexing agent, and are storage-stable, as well as non-darkening and degradation-resistant in exposure to oxygen. | 2010-03-04 |
| 20100056411 | Treating liquid for photoresist removal and method for treating substrate - Disclosed are a treating liquid for photoresist removal, containing (a) an oxidizing agent (e.g., aqueous hydrogen peroxide), (b) at least one selected from alkylene carbonates and their derivatives (e.g., propylene carbonate), and (c) water; and a method for treating with the treating liquid a substrate having a photoresist film deteriorated after dry-etching treatment thereof or a substrate optionally subjected to plasma-ashing treatment after the dry-etching treatment, and then treating it with a photoresist-stripping liquid for stripping off the photoresist. | 2010-03-04 |
| 20100056413 | HIGH-TEMPERATURE CLEANING SYSTEM, ASSOCIATED SUBSTRATES, AND ASSOCIATED METHODS - A cleaning system adapted for cleaning a surface while maintaining the surface at a temperature up to the operating temperature of the surface is disclosed. The cleaning system includes a cleaning composition and a substrate. The cleaning composition is adapted to withstand a temperature up to the operating temperature of the surface. Also, the cleaning composition includes one or more solvents, one or more surfactants, and one or more alkalinity sources or one or more acidity sources. The substrate includes a material and is adapted to communicate the cleaning composition to the soiled surface. Also, the substrate is adapted to withstand a temperature up to the operating temperature of the surface and the cleaning composition at least during the communication of the cleaning composition. | 2010-03-04 |
| 20100056414 | WAREWASHING COMPOSITION FOR USE IN AUTOMATIC DISHWASHING MACHINES, AND METHODS FOR MANUFACTURING AND USING - A warewashing detergent composition is provided according to the invention. The warewashing detergent composition includes a cleaning agent, an alkaline source, and a corrosion inhibitor. The cleaning agent comprises a detersive amount of a surfactant. The alkaline source is provided in an amount effective to provide a use composition having a pH of at least about 8. The corrosion inhibitor includes a source of aluminum ion and a source of zinc ion. The relative amounts of the source of zinc ion and the source of aluminum ion can be controlled to reduce visible filming when the warewashing detergent composition is used in the presence of hard water. Methods for using and manufacturing a warewashing detergent composition are provided. | 2010-03-04 |
| 20100056417 | DETERGENT COMPOSITION COMPRISING CELLO-OLIGOSACCHARIDE OXIDASE - The present invention relates to a detergent composition comprising cello-oligosaccharide oxidase. | 2010-03-04 |
| 20100056428 | MODIFIED PROTEINS - Method of conjugating glycoproteins by means of chemical modification is provided as well as new modified glycoproteins. | 2010-03-04 |
| 20100056429 | TREATMENT OF RESPIRATORY CHAIN DISORDERS USING COMPOUNDS HAVING ERYTHROPOIETIN OR THROMBOPOIETIN ACTIVITY - Methods of treating mitochondrial respiratory chain disorders using compounds having erythropoietin activity or thrombopoietin activity are disclosed. Indicators for assessing the efficacy of treatment are discussed. | 2010-03-04 |
| 20100056431 | MEDICAL USES - The present invention provides the use of a polypeptide comprising an amino acid sequence according to SEQ ID NO: 1 (corresponding to the N-terminal 25 amino acid fragment of the human antimicrobial protein, LL-37) or a biologically active fragment, variant, fusion or derivative thereof, in the preparation of a medicament for the treatment of cancer. In particular, the inventions provides the use such polypeptides, or a fragment, variant, fusion or derivative thereof, to inhibit the proliferation and/or metastasis of cancer cells, such as breast cancer cells. The invention further comprises methods for the treatment of cancer in a patient. | 2010-03-04 |
| 20100056433 | Novel Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity. | 2010-03-04 |
| 20100056436 | Pharmaceutical Compositions Including Low Dosages of Desmopressin - The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed. | 2010-03-04 |
| 20100056438 | Methods of producing nano-and microcapsules of spider silk proteins - The present invention is directed to a method of producing nano- and microcapsules from spider silk proteins The invention is further directed to nano- or microcapsules obtainable by this method as well as pharmaceutical, cosmetical and food compositions containing same. | 2010-03-04 |
| 20100056441 | Method for Inhibiting Angiogenesis - The invention provides methods for inhibiting angiogenesis in an animal in need thereof. The invention also pro-vides methods for preventing tumor growth and metastasis in an animal comprising inhibiting FoxM1B activity. | 2010-03-04 |
| 20100056442 | USE OF GPR101 RECEPTOR IN METHODS TO IDENTIFY MODULATORS OF HYPOTHALAMIC PROOPIOMELANOCORTIN (POMC)-DERIVED BIOLOGICALLY ACTIVE PEPTIDE SECRETION USEFUL IN THE TREATMENT OF POMC-DERIVED BIOLOGICALLY - The present invention relates to methods of using GPR101 G protein-coupled receptor (GPCR) to screen candidate compounds as modulators of hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion. Modulators of GPR101 receptor modulate hypothalamic POMC-derived biologically active peptide secretion and are useful in the treatment of POMC-derived biologically active peptide-related disorders. POMC-derived biologically active peptides include, but are not limited to, α-melanocyte stimulating hormone (α-MSH), β-melanocyte stimulating hormone (β-MSH) and γ-melanocyte stimulating hormone (γ-MSH). Agonists and partial agonists of GPR101 receptor stimulate hypothalamic α-MSH, β-MSH and γ-MSH secretion and are useful, for example, in the treatment and prevention of obesity and conditions related thereto (including but not limited to Type 2 diabetes, insulin resistance, and metabolic syndrome), inflammation-associated disorders, and pyrexia. Inverse agonists and antagonists of GPR101 receptor inhibit α-MSH, β-MSH and γ-MSH secretion and are useful, for example, in the treatment and prevention of disorders such as cachexia. | 2010-03-04 |
| 20100056443 | RADIOPHARMACEUTICAL TO BE USED IN DISTINCTION BETWEEN INFLAMMATIONS AND INFECTIONS IN ORTHOPAEDIC IMPLANTS - The present invention relates to a radio-pharmaceutical to be used in distinction between inflammations and infections in orthopaedic implants, containing one or more radiomarked human recombinant defensins of -α or -β type, in particular -β defensin of type 3. | 2010-03-04 |
| 20100056447 | IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE - The published genomic sequence of | 2010-03-04 |
| 20100056449 | Whey Protein Pre-Load - A method is provided that is effective for reducing postprandial blood glucose levels and/or food intake levels. The method includes administering native whey protein to a subject in an amount and at a time prior to a meal that is effective for reducing postprandial blood glucose levels and/or reducing food intake. | 2010-03-04 |
| 20100056450 | Method For Reducing Postprandial Blood Glucose Levels With A Whey Protein/Fiber Composition - A method is provided that is effective for reducing postprandial blood glucose levels. The method includes administering a blend of native whey protein and viscosifying fiber to a subject in an amount and at a time prior to a meal or concurrent with a meal that is effective for reducing postprandial blood glucose levels and/or reducing food intake. | 2010-03-04 |
| 20100056451 | Stabilized Pharmaceutical Peptide Compositions - Method for increasing the shelf-life of a pharmaceutical composition for parenteral administration comprising a glucagon-like peptide which is prepared from a peptide product that has been subjected to treatment at a pH above neutral pH. | 2010-03-04 |
| 20100056454 | Method for Screening Modulators of Apoptosis - The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries. | 2010-03-04 |
| 20100056455 | Therapies Which Act on Neuropeptide S Receptors - Compositions and methods that act on Neuropeptide S reseptors (NPSR) (also known as or “TGR23” or “vasopressin receptor-related receptor 1 (VRR1)”) to cause desired effects in the bodies of human or animal subjects. Neuropeptide S (NPS) and other agonists of the NPSR may be administered to cause arousal, awakening, alertness, spontaneous movement, bronchoconstriction, contraction of bronchial smooth muscle or other effects. Antagonists of the NPSR may be administered to cause decreased arousal, decreased awakening, decreased alertness, decreased spontaneous movement, sleep, somnolence, sedation, anxiolytic effects, normalized sleep patterns, normalized sleep stages, increased duration of sleep, bronchodilation, relaxation of broncheal smooth muscle or other effects. | 2010-03-04 |
| 20100056456 | Omega Conotoxins - The present invention relates to a method for increasing the binding reversibility of a ω-conotoxin to a N-type calcium channel, which comprises preparing a ω-conotoxin having a Ile and/or Ala residue at a position of amino acid (11 and/or 12), respectively in the second loop between cysteine residues (2 and 3) of the ω-conotoxin represented by the formula I, such that the prepared ω-conotoxin has the increased binding reversibility to N-type calcium channel. In addition, the present invention relates to a novel ω-conotoxin and a pharmaceutical composition having plausible properties in view of blocking activity to and specificity to N-type calcium channel, and dramatically improved binding reversibility to N-type calcium channel. | 2010-03-04 |
| 20100056489 | TREATMENT OF NEUROPATHIC PAIN - A method for treating a patient suffering from neuropathic pain, comprising administering to a patient in need of such treatment an effective amount of an agonist drug capable of binding to the neuronal nicotinic receptor (NNR) but which does not readily cross the blood-brain barrier. | 2010-03-04 |
| 20100056493 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITION AND A PROCESS OF MAKING THE SAME - The present invention refers to a modified release pharmaceutical composition comprising an in-situ gelling agent (=0.5 % w/w) and a gellation facilitating agent (e.g. calcium sulfate) in an amount of 2-17.5 % w/w. Additionally, the composition contains a release rate controlling polymer such as an acrylate and optionally a pH independent rate controlling polymer such as HPMC. A preferred active agent is mycophenolate mofetil. A process of making the above described composition is also disclosed. | 2010-03-04 |
| 20100056495 | DIMERIC IAP INHIBITORS - Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases. | 2010-03-04 |
| 20100056496 | MUSCARINIC RECEPTOR ANTAGONISTS - The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The present invention also relates to processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for treating diseases mediated through muscarinic receptors. Formula (I) or a pharmaceutically accepted salt, pharmaceutically acceptable solvate, enantiomers, diastereomer, polymorph or N-oxide thereof, wherein X is. | 2010-03-04 |
| 20100056509 | HETEROARYL SULFONAMIDES AND CCR2 - Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists. | 2010-03-04 |
| 20100056510 | Macrocyclic Compound - The present invention provides a novel class of compounds that have the activity of inhibiting HSP90 enzyme and are useful as anti-cancer agents or such, and compounds that are useful as synthetic intermediates thereof. Specifically, the present invention provides compounds represented by the following formula (1), and pharmaceutically acceptable salts thereof: | 2010-03-04 |
| 20100056511 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS - The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: R1, R2, R3, R4, R5, R6, R7, X and X | 2010-03-04 |
| 20100056512 | PYRIMIDINE COMPOUNDS - Pyrimidine compounds of the following formula: | 2010-03-04 |
| 20100056516 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS - 1-Hydroxy naphthyridine compounds (e.g., 1-hydroxy naphthyridin-2(1H)-one compounds of Formula I are inhibitors of HIV integrase and/or HIV RNase H and inhibitors of HIV replication: (I) wherein X and R1-R6 are as defined herein. The compounds are useful in the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other anti-HIV agents such as HIV antivirals, immunomodulators, antibiotics and vaccines. | 2010-03-04 |
| 20100056518 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES - The invention relates to 6-substituted isoquinolone derivatives of the formula (I) | 2010-03-04 |
| 20100056519 | COMPOSITION AND METHOD FOR REDUCING PLATELET ACTIVATION AND FOR THE TREATMENT OF THROMBOTIC EVENTS - A novel method of treating and preventing a vascular disease in an individual, comprising: selecting an individual having an elevated level of glycoprotein Ib, glycoprotein IIb/IIIa, PECAM-1, vitronectin receptor or thrombospondin receptor, or formation of platelet-neutrophil aggregates; and administering a therapeutically effective amount of a protease activated receptor-1 (PAR-1) antagonist, a pharmaceutical salt thereof, or a solvate thereof to the individual; and also, composition for treating cardiovascular diseases. | 2010-03-04 |
| 20100056521 | (AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES - The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetazolyl and the like; Y represents H, OH, NH | 2010-03-04 |
| 20100056523 | INHIBITORS OF AKT ACTIVITY - Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. | 2010-03-04 |
| 20100056524 | Compound - A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, | 2010-03-04 |
| 20100056549 | HIGHLY SOLUBLE PYRIMIDO-DIONE-QUINOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER - The present invention features pyrimido-dione-quinoline compounds having improved solubility, pharmaceutical compositions of substituted pyrimido-dione-quinoline compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more pyrimido-dione-quinoline compounds of the invention. | 2010-03-04 |
| 20100056550 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to novel substituted tricyclic heteroaromatic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2010-03-04 |
| 20100056551 | Anti-cancer cyclopenta [G] quinazoline compounds - Cyclopenta[g]quinazolines of the formula (I):—wherein: A is a group OR or NR | 2010-03-04 |
| 20100056553 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives - The invention relates to 6-substituted isoquinoline and isoquinolinone derivatives of the formula (I) | 2010-03-04 |
| 20100056556 | ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS - Heteroarylpyridinone derivatives represented by formula (I) wherein R | 2010-03-04 |
| 20100056558 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS - The invention relates to novel organic compounds of formula (I) | 2010-03-04 |
| 20100056559 | PROPELLANT-FREE AEROSOL FORMULATION FOR INHALATION - The present invention relates to propellant-free aerosol formulations for inhalation containing ipratropium bromide and salbutamol. | 2010-03-04 |
| 20100056563 | NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS - The present invention relates to naphthyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions. | 2010-03-04 |
| 20100056565 | Heterocyclic Derivatives as M3 Muscarinic Receptors - This invention relates to M3 antagonists of formula (I) wherein R | 2010-03-04 |
| 20100056567 | NOVEL ALKYL SUBSTITUTED PIPERIDINE DERIVATIVES AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel alkyl substituted piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 2010-03-04 |
| 20100056609 | METHODS AND COMPOSITIONS FOR INHIBITION OF AXONAL DEGENERATION BY MODULATION OF THE DLK/JNK PATHWAY - Methods of reducing Wallerian degeneration are disclosed. These methods comprise inhibiting expression or activity of a mixed lineage kinas such as a dual leucine-zipper-bearing kinase (DLK), inhibiting expression or activity of a molecule acting downstream from DLK, such as a c-Jun N-terminal kinase (JNK), or a combination thereof. Further disclosed are methods of screening candidate compounds for DLK inhibition activity. These methods comprise providing a neuronal culture comprising a plurality of axons; contacting the culture with a candidate compound and with an axon degeneration-triggering agent; and comparing axonal degeneration in the culture to a control culture comprising the axon degeneration-triggering agent but not the candidate compound. | 2010-03-04 |
| 20100056610 | HEPTbeta AS A TARGET IN TREATMENT OF ANGIOGENISIS MEDIATED DISORDERS - Disclosed herein is the use of HPTPbeta to screen agents useful in the treatment angiogenesis mediated disorders. | 2010-03-04 |
| 20100056611 | MN/CA9 Splice Variants - Herein disclosed is an alternatively-spliced [AS] variant of MN/CA9 mRNA and its related protein—AS MN/CA IX. Unlike the tumor-associated, full-length [FL] MN/CA9 mRNA and FL MN/CA IX, which in most tissues signify oncogenesis and/or hypoxia, the AS MN/CA9 mRNA is constitutively-expressed under normoxia and is not stimulated by hypoxia, and the AS MN/CA IX is not confined to the cell membrane. Provided herein are diagnostic/prognostic methods for preneoplastic/neoplastic disease to differentiate between AS and FL MN/CA9 expression, and probes, primers, and antibodies useful in such methods. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, which methods are based on the ability of AS MN protein (AS MN/CA IX) to interfere with the catalytic activity of FL MN protein (FL MN/CA IX); such methods may also use AS MN protein fragments that have that interference capability. Such methods may comprise increasing the levels of AS MN/CA IX relative to the levels of FL MN/CA IX. Exemplary therapeutic methods may comprise the administration of agents, such as, AS MN/CA IX itself, a vector expressing AS MN/CA9 mRNA, an antisense oligonucleotide that blocks expression of FL MN/CA IX but not that of AS MN/CA IX, a vector expressing such an antisense oligonucleotide, a FL MN/CA9 isoform-specific siRNA, or a vector expressing such FL MN/CA9 isoform-specific siRNA. Further disclosed are methods to identify agents capable of modulating levels of AS MN/CA IX. | 2010-03-04 |
| 20100056612 | MOLECULAR ENTITIES FOR BINDING, STABILIZATION AND CELLULAR DELIVERY OF CHARGED MOLECULES - In accordance with the present invention, it has been discovered that the uptake of charged molecules into cells can be enhanced by noncovalently associating such molecules with molecular entities comprising an amphiphilic core with oppositely charged arms. The molecular entities form well defined stoichiometric complexes with charged molecules. Various compositions and methods for stabilizing anionic charged molecules and for enhancing the cellular uptake of any anionic charged molecules, e.g. double-stranded or hairpin nucleic acid, are provided. | 2010-03-04 |
| 20100056613 | SPIROQUINONE COMPOUND AND PHARMACEUTICAL COMPOSITION - A novel spiroquinone derivative having a high ABCA1 stabilization effect and being useful for prophylactic and/or therapeutic agents for various diseases developing hypo-high density lipoproteinemia is obtained. The novel spiroquinone derivative is a compound represented by the following formula: | 2010-03-04 |
| 20100056615 | USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS - The present invention refers to the use of at least one tricyclic diterpenes for the manufacture of a nutraceutical or pharmaceutical for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders. | 2010-03-04 |
| 20100056616 | IEJIMALID ANALOGA AND USES THEREOF - The invention relates to Iejimalides having the following formula (I) in which a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p are simple or double bonds, the continuous lines representing at least one simple bond, the dotted lines representing a possible bond. A double bond can be present but it is not necessary, and provided that a continuous line is also present, or a simple bond can be present if no other line is represented; m=0-20 and n1-n18=1, 2. The bonds can be used as chemotherapeutic agents for treating cancer. | 2010-03-04 |
| 20100056620 | ACTIVE COMPOUND COMBINATIONS WITH INSECTICIDAL AND ACARICIDAL PROPERTIES - The novel active compound combinations consisting, firstly, of cyclic ketoenols and, secondly, of beneficial species (natural enemies) have very good insecticidal and/or acaricidal properties. | 2010-03-04 |
| 20100056621 | AGONISTS OF A BITTER TASTE RECEPTOR AND USES THEREOF - The present invention relates to agonists of the hTAS2R14 bitter taste receptor and its role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R14 bitter taste transduction or bitter taste response. | 2010-03-04 |
| 20100056622 | Methods of Using Ramelteon to Treat Patients Suffering from a Variety of Neurodegenerative Diseases - Methods of using ramelteon to treat patients suffering from a variety of neurodegenerative diseases are disclosed. | 2010-03-04 |
| 20100056623 | FUMAGILLOL DERIVATIVES OR METHOD FOR PREPARATION OF FUMAGILLOL DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - The present invention relates to a fumagillol derivative, pharmaceutically acceptable salts thereof and a method for preparing the same. The compounds of the present invention can be prepared through acylation, hydrolysis and alkylation. The compound of the present invention can be prepared in the form of a pharmaceutically acceptable salt or inclusion compound. The present invention provides fumagillol derivatives having the following characteristics: increased inhibiting effect on angiogenesis, low toxicity, excellent solubility and chemical stability as compared to conventional angiogenesis inhibitors. The compounds of the present invention can be used as an anti-cancer medicine, inhibitor of cancer metastasis, or the therapeutic agent for treating rheumatic arthritis, psoriasis, diabetic retinitis or obesity. | 2010-03-04 |
| 20100056638 | Oral and Injectable Formulations of Tetracycline Compounds - Injectable and oral formulations of a tetracycline compound are described. In one embodiment, the invention pertains to an oral formulation of a 9-aminomethyl tetracycline compound, or a salt thereof, in tablet form or capsule. The formulations may be used, for example, to treat infections. | 2010-03-04 |
| 20100056639 | INSECTICIDAL COMPOUNDS - A compound of formula (I): wherein A | 2010-03-04 |
| 20100056643 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA - An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation. | 2010-03-04 |
| 20100056644 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANHYDROUS CALCIPOTRIENE - A stable pharmaceutical composition in a semisolid dosage form comprising a therapeutic effective amount of solubilized calcipotriene in an anhydrous form is disclosed. | 2010-03-04 |
| 20100056645 | Chromatographic Media and Chromatographic Equipment Storage Solutions and Use Thereof - Buffered antimicrobial solutions of benzyl alcohol and ethanol and their use for short or long term storage of chromatographic solids. | 2010-03-04 |
| 20100056648 | Processes and systems for production of liquefied petroleum gas (LPG) - The present invention relates generally to processes and systems for the production of liquefied petroleum gas (LPG). More specifically, embodiments of the present invention relate to improved methods and systems for the direct reaction of synthesis gas (syngas) to liquefied petroleum gas. | 2010-03-04 |
| 20100056650 | Membrane Production - The present invention is a method for forming a hydrophilic polymer membrane for use in a membrane electrode assembly, comprising the polymerisation of a material or materials from which the membrane may be formed, wherein the polymerisation is by UV curing. | 2010-03-04 |
| 20100056651 | METHOD FOR CAPTURING AND SEQUESTERING CARBON CONTAINED IN PLASTICS - A method for sequestering carbon contained in waste plastic includes separating the waste plastic from the waste stream prior to incineration, gasification, landfill, or any other method of final disposal of waste, modifying the plastic for use as a modified polymer aggregate, and using the modified polymer aggregate as a constituent ingredient in a durable building material. | 2010-03-04 |
| 20100056654 | BONE CEMENT WITH ADAPTED MECHANICAL PROPERTIES - A bone cement is shown that includes a monomer, and a non-reactive substance that is fully miscible with the monomer. A resulting cured bone cement exhibits desirable properties such as modification in a stiffness of the material. Modified properties such a stiffness can be tailored to match bone properties and reduce an occurrence of fractures adjacent to a region repaired with bone cement. One example includes adjacent vertebral body fractures in vertebroplasty procedures. | 2010-03-04 |
| 20100056655 | GYPSUM PRODUCTS UTILIZING A TWO-REPEATING UNIT DISPERSANT AND A METHOD OF MAKING THEM - A gypsum slurry includes water, a hydraulic component including stucco and a polycarboxylate dispersant. The dispersant has two repeating units wherein the first repeating unit is an olefinic unsaturated mono-carboxylic acid repeating unit or an ester or salt, and the second repeating unit is a vinyl or allyl group bound to a polyether by an ether linkage. The slurry can be made into a gypsum panel. | 2010-03-04 |
| 20100056658 | TRANS-1,2 DICHLOROETHYLENE COMPOSITION - The present invention relates to a composition based on trans- | 2010-03-04 |
